Thursday, December 3rd, 2020

  • Yehuda Handelsman, MD

    Welcome to the 18th WCIRDC Slides

  • Robert Chilton, DO

    The Myocardium: Too Fat to be Fit

  • Ralph DeFronzo, MD

    Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome

  • Kenneth Cusi, MD

    Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of "Foie Gras"

  • Eric Ravussin, PhD

    The Beta Cell- Insulin Resistance Connection: A Fat Story

  • Martha Gulati, MD

    Sex Differences in Coronary Artery Calcium and Long-Term CV Mortality

  • Gina P. Lundberg, MD

    Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women

  • Howard Hodis, MD

    Hormone Replacement Therapy, Atherosclerosis and Cardiovascular Disease: An Update

  • Paul Zimmet, AO, MD, PhD

    Two Pandemics in Collision: COVID-19 and Diabetes

  • Stefan Bornstein, MD

    Managing Patients with Diabetes and COVID-19

  • Geltrude Mingrone,MD

    Obesity and Metabolic Surgery During and Beyond COVID-19

  • Derek LeRoith, MD, PhD

    Overview of The Interaction Between Obesity, Diabetes and Cancer Therapy

  • Emily Gallagher, MD, PhD

    The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism

  • Kevan Herold, MD

    Immunobiologics Effect on Diabetes: Type 1 And Type 2

  • Richard Bergman, PhD

    Important Role of Reduced Insulin Clearance in Pathogenesis of Type 2 Diabetes: Hypothesis and Experimental Confirmation in Man

CME Satellite Symposium:

Heart Failure and Kidney Disease: The Next Epidemics 

Supported by AstraZeneca

  • Maria Rosa Costanzo, MD

    Epidemiology and Traditional Management of HF and CKD

  • Mikhail Kosiborod, MD

    The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF

  • Katherine Tuttle, MD

    Revolution in the Management of Moderate to Severe CKD

  • Muthiah Vaduganathan, MD

    Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD

Friday, December 4th, 2020

  • Aaron Kelly, PhD

    The Ceramide Pathway as a Target for Insulin Sensitization

  • Thomas Inge, MD, PhD

    Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults

  • Sonia Caprio, MD

    Sleeve Gastrectomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls

  • Philipp Scherer, PhD

    The Ceramide Pathway as a Target for Insulin Sensitization

  • Gerald Shulman, MD, PhD

    Diacylglycerols and acetyl-CoA as a Therapeutic Targets for Insulin Resistance and Type 2 Diabetes

  • Kausik Ray, MD

    New Agents: PCSK9 siRNA (inclisiran) and Bempedoic Acid

  • Robert Rosenson, MD

    Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research

  • Norman Lepor, MD

    The Role of LP(a) & ANGPTL3 in Lipids Atherosclerosis and Cardiovascular Disease

  • Jay Skyler, MD

    Islet Cell Preservation & Replacement

  • Ronald Evans, PhD

    Stem Cell Generated Human Islets- Rescue Diabetes Without a Device

  • George Grunberger, MD

    State of the Art Insulin Delivery Systems

  • Julio Rosenstock, MD

    Tomorrow’s New Insulin Today

  • James Sowers, MD

    Insulin Resistance and Cardiovascular Disease

  • Dimitri Mikhailidis, MD

    Insulin resistance, NAFLD/NASH and CVD Risk

  • Gerald Watts, MD

    Go with the Flow: Understanding Lipid Metabolism with Tracer Methods

  • Michael Snyder, PhD

    Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging

  • Tracey McLaughlin, MD

    Continuous Glucose Monitoring for Precision Diets

  • Jerome Rotter, MD

    The Genetic Interrelationship Between T2D & Coronary Heart Disease

Saturday, December 5th, 2020

  • Christos Mantzoros, MD, PhD

    NASH- The Status of Diagnostics and Therapeutics

  • Bart Staels, PhD

    The Sexually Dimorphic Nature of NASH May Impact on Disease Progression and Responses To Drugs

  • Jorge Plutzky, MD

    Anti-Inflammatory Impact on Atherosclerosis: CVOT and Management Implications

  • Matthew Budoff, MD

    Impact of Non Statin Drugs On Plaque Formation and Atherosclerosis

  • Peter Reaven, MD

    GLP1ra and Atherosclerosis- Human Data at Last

  • Kevin Hall, PhD

    The Influence of Dietary Carbs, Fat, And Quality on Ad Libitum Calorie Intake

  • W. Timothy Garvey, MD

    Future of Obesity Pharmacotherapy: New Drugs and New Targets

  • Philip Schauer, MD

    Effects of Bariatric Surgery on Cardiovascular Events

  • Samuel Klein, MD

    Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects?

  • Peter A. McCullough, MD

    Pathophysiological Basis & Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

  • Erin D. Michos, MD

    Sex Differences in Mortality from COVID-19 Pandemic

  • Ajay Nirula, MD, PhD

    The Role of Neutralizing Antibody Therapy in the Management of COVID-19

  • Tracey McLaughlin, MD

    Obesity & COVID-19

CME Satellite Symposium:

Emerging Standard of Care in the Prevention of Cardiovascular Morbidity and Mortality

Supported by Amarin

  • Deepak Bhatt, MD

    Primary and Secondary Prevention of CVD – Current standard of Care

  • Neha Pagidipati, MD

    High TGL association with ASCVD- Epidemiology and pathophysiology

  • Matthew Budoff, MD

    IPE impact on ASCVD Morbidity and Mortality

  • Yehuda Handelsman, MD

    Lipid Guidelines IPE related

Sunday, December 6th, 2020

  • Peter Grant, MD

    Insulin Resistance And Thrombotic Risk: Implications For Therapeutic Approaches To Vascular Disease

  • Sanjay Kaul, MD

    Update of Recent CV Outcome Trials

  • Brendan Everett, MD

    The ACC’s Expert Consensus Decision Pathway: Improving Cardiovascular Outcomes in Type 2 Diabetes

  • Mikhail N. Kosiborod, MD

    The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance

  • Francesco Giorgino, MD

    Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i, GLP-1RA or Initial Combination of Both?

  • Vivian Fonseca, MD

    Hypoglycemia Impact and Management

  • Richard Bergenstal, MD

    The Role of CGM in Diabetes Update toward 2021

  • Robert Eckel, MD

    The Current Management of CV Risk factors in Type 1 Diabetes

  • Richard Pratley, MD

    DEBATE: Should T2D Medications with Proven CV Benefits be Used in T1D to Prevent ASCVD: Yes

  • David Nathan, MD

    Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes

  • Matthew Weir, MD

    KDIGO- Diabetes CKD and Hypertension New Guidelines

  • David Cherney, MD

    GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold?

  • Monica Aggarwal, MD

    Lifestyle Modifications for Preventing and Treating Heart Failure

  • Carolyn Lam Su Ping, PhD

    All We Need to Know about HFpeF

  • Javed Butler, MD

    Update on HFOT impact on Management - Sequencing vs Initial Combination of Medication

18372 Clark Street

Suite 212

Tarzana, CA 91356

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter